Sam Brusco, Associate Editor02.29.24
Orthofix has promoted Jason Shallenberger as president of its Bone Growth Therapies business. The company is also realigning its Spine business unit. Both will take effect on March 1, 2024.
Shallenberger began his tenure at Orthofix in 2005 as a territory manager and quickly moved to district sales manager, before promotion to regional sales director in 2008. He was again promoted to VP of U.S. sales and marketing in 2011, and given further medical education responsibilities last year. Before Orthofix, he was a specialty sales rep with Boehringer Ingelheim.
“Since 1986, Orthofix Bone Growth Therapy has helped promote the natural-bone healing process in patients,” said Shallenberger. “I am honored to continue my career with the company in this new role as we continue to innovate and bring new technologies to the market.”
Before the realignment, Bone Growth Therapies was managed under leadership of the company’s Spine business. The two segments will now be led by separate presidents, aligned to the current business structures of Biologics and Enabling Technologies.
“Jason has led sales and marketing for this successful franchise for a number of years,” said Orthofix president and CEO Massimo Calafiore. “Under his guidance, the sales team has produced quarter-after-quarter of double-digit growth in 2023. I am confident he will do an amazing job as President and continue to contribute greatly to the success of Orthofix.”
Calafiore began his tenure as Orthofix’s new chief executive last month.
Shallenberger began his tenure at Orthofix in 2005 as a territory manager and quickly moved to district sales manager, before promotion to regional sales director in 2008. He was again promoted to VP of U.S. sales and marketing in 2011, and given further medical education responsibilities last year. Before Orthofix, he was a specialty sales rep with Boehringer Ingelheim.
“Since 1986, Orthofix Bone Growth Therapy has helped promote the natural-bone healing process in patients,” said Shallenberger. “I am honored to continue my career with the company in this new role as we continue to innovate and bring new technologies to the market.”
Before the realignment, Bone Growth Therapies was managed under leadership of the company’s Spine business. The two segments will now be led by separate presidents, aligned to the current business structures of Biologics and Enabling Technologies.
“Jason has led sales and marketing for this successful franchise for a number of years,” said Orthofix president and CEO Massimo Calafiore. “Under his guidance, the sales team has produced quarter-after-quarter of double-digit growth in 2023. I am confident he will do an amazing job as President and continue to contribute greatly to the success of Orthofix.”
Calafiore began his tenure as Orthofix’s new chief executive last month.